as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹112.2
Change
+4.45 (4.13%)
Open
₹108.97
Prev. Close
₹107.75
Day High
₹113.13
Day Low
₹106.36
Volume Analysis
Traded
264,554
Delivered
207,736
Delivery %
78.52%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Promoter holding is falling
- •Below-average fundamentals quality score (43/100)
- •Low operating margin (1.5%)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹121.53 | ₹117.33 | ₹114.76 | ₹110.56 | ₹107.99 | ₹103.79 | ₹101.22 |
| Fibonacci | ₹117.33 | ₹114.74 | ₹113.15 | ₹110.56 | ₹107.97 | ₹106.38 | ₹103.79 |
| Camarilla | ₹114.06 | ₹113.44 | ₹112.82 | ₹110.56 | ₹111.58 | ₹110.96 | ₹110.34 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+66.1%
1 Week
-1.67%
1 Month
+0.24%
3 Months
+38.18%
6 Months
+33.99%
1 Year
+18.64%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
2.36%
Net margin 0.85% × asset turnover 1.5x × equity multiplier 1.85x
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Aarey Drugs & Pharm Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 43/100. The strongest factor is Financial Strength (98/100), while Growth (12/100) is the weakest area to weigh before deciding. Notably: Promoter holding is falling; below-average fundamentals quality score (43/100).
TopFund Score — Fundamentals Quality
43/100 — WeakData confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Cash Flow
Corporate Governance
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Pursuant to Regulation 47 of SEBI (LODR) Regulation, 2015, the company has published and extract of statement of unaudited standalone Financial ....
Aarey Drugs reports no deviation in warrant proceeds; ₹2,481.82 lakh received, ₹900 lakh unutilised as of 30 Sep 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 (S) | Dec 2023 (S) | Mar 2024 (S) | Jun 2024 (S) | Sep 2024 (S) | Dec 2024 (S) | Mar 2025 (S) | Jun 2025 (S) | Sep 2025 (S) | Dec 2025 (S) | Mar 2026 (S) | Jun 2026 (S) | Sep 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 58 | 76 | 210 | 127 | 105 | 134 | 108 | 102 | 84 | 96 | 189 | 45 | 89 |
| Expenses + | 56 | 74 | 212 | 126 | 101 | 132 | 112 | 101 | 82 | 98 | 185 | 43 | 86 |
| Operating Profit | 2 | 3 | -1 | 1 | 4 | 2 | -4 | 2 | 3 | -2 | 4 | 1 | 2 |
| OPM % | 3.18% | 3.53% | -0.68% | 0.93% | 3.54% | 1.64% | -3.89% | 1.67% | 3.14% | -1.57% | 2.29% | 2.96% | 2.41% |
| Other Income + | 1 | 0 | 5 | 2 | 0 | 1 | 8 | 2 | 1 | 4 | 0 | 2 | 2 |
| Interest | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 1 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| Tax % | -22.0% | 30.14% | -0.47% | 6.77% | 8.62% | 48.57% | 71.6% | 20.81% | 31.08% | 38.04% | -21.88% | -98.08% | 17.47% |
| Net Profit + | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 1 | 1 |
| EPS in Rs | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -24 | 22 | 29 | 149 | 82 | 75 | -49 | -19 | -20 | -28 | 75 | -56 | 5 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 213 | 246 | 396 | 349 | 354 | 298 | 348 | 493 | 419 | 396 | 474 | 472 |
| Expenses + | 212 | 245 | 386 | 342 | 347 | 294 | 344 | 481 | 411 | 391 | 471 | 465 |
| Operating Profit | 1 | 1 | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 4 | 3 | 7 |
| OPM % | 0.6% | 0.4% | 2.4% | 2.2% | 2.2% | 1.1% | 1.3% | 2.3% | 1.8% | 1.1% | 0.6% | 1.5% |
| Other Income + | 3 | 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | 7 | 10 | 6 |
| Interest | 1 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 5 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 1 | 2 | 8 | 8 | 9 | 7 | 8 | 10 | 6 | 5 | 6 | 5 |
| Tax % | 23.0% | 29.0% | 31.0% | 25.0% | 27.0% | 20.0% | 21.0% | 35.0% | 37.0% | 12.0% | 34.0% | 27.0% |
| Net Profit + | 1 | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 4 | 4 |
| EPS in Rs | 1 | 1 | 3 | 3 | 3 | 2 | 3 | 3 | 1 | 2 | 1 | 1 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Sales growth | 7 | 15 | 61 | -12 | 1 | -16 | 17 | 41 | -15 | -6 | 20 | 0 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | Sep 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 19 | 20 | 31 | 57 | 63 | 69 | 75 | 88 | 92 | 105 | 110 | 122 | 138 |
| Borrowings + | 11 | 15 | 10 | 3 | 16 | 18 | 18 | 14 | 38 | 31 | 35 | 50 | 56 |
| Other Liabilities + | 69 | 74 | 83 | 86 | 43 | 84 | 116 | 117 | 136 | 139 | 117 | 97 | 89 |
| Total Liabilities | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 | 297 | 315 |
| Fixed Assets + | 6 | 8 | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 13 | 16 | 18 | 21 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Other Assets + | 109 | 117 | 130 | 157 | 133 | 181 | 218 | 230 | 277 | 289 | 272 | 269 | 289 |
| Total Assets | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 | 297 | 315 |
| Equity Capital | 17 | 17 | 18 | 23 | 23 | 23 | 23 | 25 | 25 | 28 | 28 | 28 | 32 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 (S) | Mar 2023 (S) | Mar 2024 (S) | Mar 2025 (S) | Mar 2026 (S) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 3 | 6 | 1 | -20 | 1 | 3 | 5 | 0 | -1 | -3 | 10 | 10 |
| Cash from Investing Activity + | -2 | -3 | -5 | -1 | -1 | -1 | -3 | -3 | 0 | -2 | -6 | -12 |
| Cash from Financing Activity + | -2 | -2 | 4 | 23 | -2 | -2 | -2 | 2 | 1 | 6 | -4 | 2 |
| Net Cash Flow | -1 | 1 | -1 | 2 | -3 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Free Cash Flow | 1 | 3 | -4 | -21 | -1 | 2 | 3 | -2 | -2 | -4 | 5 | -2 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 239 | 560 | 28 | -232 | 37 | 135 | 154 | 36 | 13 | -37 | 421 | 164 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 46.12% | 51.31% | 51.32% | 51.81% | 52.86% | 52.86% | 53.23% | 54.07% | 57.09% | 56.49% | 55.87% | 52.83% |
| Promoters | 50.04% | 45.28% | 45.28% | 45.44% | 44.8% | 44.8% | 44.8% | 44.8% | 39.05% | 37.71% | 37.71% | 41.46% |
| FII | 3.83% | 3.4% | 3.4% | 2.75% | 2.34% | 2.34% | 1.97% | 1.13% | 3.86% | 4.18% | 4.81% | 4.28% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.62% | 1.62% | 1.44% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Aarey Drugs & Pharm Ltd (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 451,075 | 36.7 | 5.05 | 16.0% |
| Divi S Laboratories Ltd | 294,139 | 86.1 | 16.34 | 16.5% |
| Torrent Pharmaceuticals L | 177,632 | 81.8 | 9.67 | 27.4% |
| Apollo Hospitals Enter. L | 125,893 | 55.6 | 11.86 | 21.5% |
| Laurus Labs Limited | 125,380 | 93.6 | 20.73 | 18.3% |
| Zydus Lifesciences Ltd | 118,693 | 26.2 | 4.27 | 21.2% |
Which Mutual Funds Hold Aarey Drugs & Pharm Ltd?
Frequently Asked Questions about Aarey Drugs & Pharm Ltd
Aarey Drugs & Pharm Ltd (AAREYDRUGS) closed at ₹112.2 on NSE on 19 November 2026, up 4.45 (4.13%) from the previous close.
Aarey Drugs & Pharm Ltd trades on the NSE (National Stock Exchange of India) under the symbol AAREYDRUGS.
Aarey Drugs & Pharm Ltd has a TopFund Quality Score of 43/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Aarey Drugs & Pharm Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.